Lisata Therapeutics Net Income vs. EBITDA

LSTA Stock  USD 2.82  0.02  0.70%   
Based on Lisata Therapeutics' profitability indicators, Lisata Therapeutics may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in December. Profitability indicators assess Lisata Therapeutics' ability to earn profits and add value for shareholders.
 
Net Loss  
First Reported
1994-06-30
Previous Quarter
-5 M
Current Value
-4.9 M
Quarterly Volatility
7.6 M
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
At present, Lisata Therapeutics' Price To Sales Ratio is projected to drop slightly based on the last few years of reporting. The current year's Price Sales Ratio is expected to grow to 0.12, whereas Days Sales Outstanding is forecasted to decline to 1.57. At present, Lisata Therapeutics' Total Other Income Expense Net is projected to increase significantly based on the last few years of reporting. The current year's Change To Netincome is expected to grow to about 5.5 M, whereas Accumulated Other Comprehensive Income is forecasted to decline to (44.1 K).
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.740.6
Fairly Up
Slightly volatile
For Lisata Therapeutics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Lisata Therapeutics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Lisata Therapeutics utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Lisata Therapeutics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Lisata Therapeutics over time as well as its relative position and ranking within its peers.
  
Check out Correlation Analysis.
For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lisata Therapeutics. If investors know Lisata will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lisata Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.51)
Return On Assets
(0.29)
Return On Equity
(0.44)
The market value of Lisata Therapeutics is measured differently than its book value, which is the value of Lisata that is recorded on the company's balance sheet. Investors also form their own opinion of Lisata Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lisata Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lisata Therapeutics' market value can be influenced by many factors that don't directly affect Lisata Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lisata Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lisata Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lisata Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Lisata Therapeutics EBITDA vs. Net Income Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Lisata Therapeutics's current stock value. Our valuation model uses many indicators to compare Lisata Therapeutics value to that of its competitors to determine the firm's financial worth.
Lisata Therapeutics is rated below average in net income category among its peers. It also is rated below average in ebitda category among its peers . At present, Lisata Therapeutics' Net Loss is projected to increase significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Lisata Therapeutics' earnings, one of the primary drivers of an investment's value.

Lisata EBITDA vs. Net Income

Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Lisata Therapeutics

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(20.84 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

Lisata Therapeutics

EBITDA

 = 

Revenue

-

Basic Expenses

 = 
(25.52 M)
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Lisata EBITDA Comparison

Lisata Therapeutics is currently under evaluation in ebitda category among its peers.

Lisata Therapeutics Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Lisata Therapeutics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Lisata Therapeutics will eventually generate negative long term returns. The profitability progress is the general direction of Lisata Therapeutics' change in net profit over the period of time. It can combine multiple indicators of Lisata Therapeutics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-42 K-44.1 K
Operating Income-25.7 M-27 M
Income Before Tax-23.2 M-24.3 M
Total Other Income Expense Net2.5 M2.7 M
Net Loss-20.8 M-21.9 M
Income Tax Expense-2.3 M-2.2 M
Net Loss-20.8 M-21.9 M
Net Loss-24.7 M-26 M
Change To Netincome5.2 M5.5 M
Net Loss(2.58)(2.71)
Income Quality 0.96  1.01 
Net Income Per E B T 0.90  0.48 

Lisata Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Lisata Therapeutics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Lisata Therapeutics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Lisata Therapeutics' important profitability drivers and their relationship over time.

Use Lisata Therapeutics in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lisata Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lisata Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Lisata Therapeutics Pair Trading

Lisata Therapeutics Pair Trading Analysis

The ability to find closely correlated positions to Lisata Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lisata Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lisata Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lisata Therapeutics to buy it.
The correlation of Lisata Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lisata Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lisata Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lisata Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Lisata Therapeutics position

In addition to having Lisata Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Education Thematic Idea Now

Education
Education Theme
Companies involved in apprenticeship, education, tutoring, schooling, online universities, and other learning services. The Education theme has 45 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Education Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Lisata Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lisata Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lisata Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lisata Therapeutics Stock:
Check out Correlation Analysis.
For information on how to trade Lisata Stock refer to our How to Trade Lisata Stock guide.
You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
To fully project Lisata Therapeutics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Lisata Therapeutics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Lisata Therapeutics' income statement, its balance sheet, and the statement of cash flows.
Potential Lisata Therapeutics investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Lisata Therapeutics investors may work on each financial statement separately, they are all related. The changes in Lisata Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Lisata Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.